Gene therapy Improves Eye Health and Reduces the Need for Anti-VEGF Injections in Age-Related Macular Degeneration.
RegenxBio, a publicly-traded biotech firm, released data this week from a Phase 2 clinical trial designed to test its leading genetic therapy product in patients with bilateral wet age-related macular degeneration (AMD). AMD is characterized by abnormal growth of blood vessels…
Read More